HAS3 silencing or treatment with the CD44 antibody combined with CQ exerted a synergistic effect on reducing the viability of glioma cells and levels of the Ki67 protein (Figs. 4B–D and 5A). This evidence concerns the gene CD44 and central nervous system cancer.